01—Abstract
Summary
Summary of the 8-K filed March 28, 2024. Cited figures are marked; the original filing is the authoritative source.
This 8-K filing from Astera Labs, Inc. (ALAB) primarily details the completion of its Initial Public Offering (IPO) on March 22, 2024.
The company successfully offered 22,770,000 shares of Common Stock at an initial price of $36.00a per share. Of these, 19,758,903 shares were sold by Astera Labs itself, including the full exercise of the underwriters' option for an additional 2,970,000 shares. Certain selling stockholders also sold 3,011,097 shares, with the company not receiving proceeds from those sales.
Furthermore, the filing confirms the automatic conversion of all outstanding preferred stock into 90,890,650 shares of common stock, which occurred immediately prior to the IPO's closing. This conversion was conducted on a one-for-one basis and was not registered under the Securities Act of 1933, relying on an exemption for unregistered sales of equity securities. The company also updated its corporate governance documents, filing an amended and restated certificate of incorporation and bylaws, effective upon the IPO's consummation.
02—Key points
Key Highlights
- Astera Labs completed its Initial Public Offering (IPO) on March 22, 2024, offering 22,770,000 shares of Common Stock at $36.00 per share.
- The company sold 19,758,903 shares, including the full exercise of the underwriters' option to purchase an additional 2,970,000 shares.
- Selling stockholders sold 3,011,097 shares, with no proceeds from these sales going to the company.
- Prior to the IPO, all outstanding preferred stock (Series A, A-1, B, B-1, C, and D) was converted into 90,890,650 shares of common stock on a one-for-one basis.
- The conversion of preferred stock to common stock was an unregistered sale of equity securities, relying on the exemption under Section 3(a)(9) of the Securities Act of 1933.
- The company filed an amended and restated certificate of incorporation and second amended and restated bylaws, effective with the IPO closing.
- The filing effectively confirms the transition from a private company with preferred stock to a publicly traded company with common stock.
03—Questions
Frequently Asked Questions
What is the main purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report the completion of Astera Labs' Initial Public Offering (IPO) and to disclose related corporate actions, such as the conversion of preferred stock to common stock and the filing of updated corporate governance documents.
How many shares were offered in the IPO and at what price?
Astera Labs completed its IPO by offering a total of 22,770,000 shares of Common Stock at an initial public offering price of $36.00 per share.
Were all the shares sold in the IPO by the company?
No, while the company sold 19,758,903 shares (including the exercise of the underwriters' option), an additional 3,011,097 shares were sold by certain selling stockholders. Astera Labs did not receive any proceeds from the shares sold by these stockholders.
What happened to the company's preferred stock in relation to the IPO?
Immediately prior to the closing of the IPO, all outstanding shares of the company's preferred stock (Series A, A-1, B, B-1, C, and D) were automatically converted into an equal number of shares of common stock (90,890,650 shares total). This conversion was conducted on a one-for-one basis and was not registered with the SEC, relying on a specific exemption.
04—Continue